本系统综述旨在评估口腔HPV相关病变的患病率。归类为良性(寻常疣“VV”,鳞状细胞乳头状瘤\"SP\",尖锐湿疣\“CA\”,和局灶性上皮增生\“FEH\”)和恶性(口腔鳞状细胞癌\“OSCC\”),按儿科受试者(≤18岁)的发生率降序排列。次要目的是评估与HPV基因型和HPV疫苗类型(如果有的话)相关描述的口腔病变的频率和类型。研究方案,符合PRISMA声明,在PROSPERO注册(CRD42022352268)。来自60项研究的数据,使用ROBINS-I工具评估其质量,被独立提取和合成。除了七个描述不佳的良性HPV相关口腔病变,无法分类,共146例HPV相关口腔病变,即47.26%(n=69)VV,SP,CA,51.37%(n=75)FEH,和1.37%(n=2)OSSC,在153名儿科受试者(M:F比率=1:1.4)中诊断出病变的平均年龄为8.46岁。检测到的病毒基因型为HPV-13(30.61%),-6(20.41%),-11(16.33%),HPV-2(12.24%),-32(10.20%),-57(6.12%),和-16(4.08%)。在任何情况下都没有报告HPV疫苗接种。应进行进一步的研究以评估HPV相关良性和恶性病变的患病率以及HPV和相关疫苗接种在儿科受试者口腔癌变中的潜在作用。
The present systematic review aimed to assess the prevalence of oral HPV-related lesions, categorized as benign (verruca vulgaris \"VV\", squamous cell papilloma \"SP\", condyloma acuminata \"CA\", and focal epithelial hyperplasia \"FEH\") and malignant (oral squamous cell carcinoma \"OSCC\"), in descending order of occurrence in pediatric subjects (≤18 years of age). The secondary objectives were to evaluate the frequency and types of oral lesions described in relation to HPV genotypes and the HPV vaccine type (if any). The study protocol, compliant with the PRISMA statement, was registered at PROSPERO (CRD42022352268). Data from 60 studies, of which quality was assessed using the ROBINS-I tool, were independently extracted and synthesized. Along with seven poorly described benign HPV-related oral lesions that could not be categorized, a total of 146 HPV-related oral lesions, namely 47.26% (n = 69) VV, SP, and CA, 51.37% (n = 75) FEH, and 1.37% (n = 2) OSSC, were diagnosed in 153 pediatric subjects (M:F ratio = 1:1.4) with a mean age of lesion onset of 8.46 years. The viral genotypes detected were HPV-13 (30.61%), -6 (20.41%), -11 (16.33%), HPV-2 (12.24%), -32 (10.20%), -57 (6.12%), and -16 (4.08%). No HPV vaccination was reported in any case. Further studies should be conducted to evaluate the prevalence of HPV-related benign and malignant lesions and the potential role of HPV and associated vaccination in oral carcinogenesis in pediatric subjects.